{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031718","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.959715+00:00","generated_at":"2026-05-31T09:25:28.944685+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Calidi Biotherapeutics reports Q2 2024 net loss of $5.8M; cash at $1.0M; launches Nova Cell subsidiary","bullets":["Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.","Cash and restricted cash total ~$1.0M as of June 30, 2024, down from $2.1M at Dec 31, 2023.","Launched Nova Cell subsidiary with $2M investment from Dr. Ronald Rigor; received additional $1M into Calidi.","Appointed Dr. George Peoples to Board of Directors and Dr. Mark Gilbert to Medical Advisory Board.","Received new U.S. patent for SuperNova technology; raised $2.5M from warrant exercises in July/August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031718","json":"https://secwatch.observer/filing/0001493152-24-031718.json","markdown":"https://secwatch.observer/filing/0001493152-24-031718.md","text":"https://secwatch.observer/filing/0001493152-24-031718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/0001493152-24-031718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:25:28.944685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}